Liquid chromatography tandem mass spectrometry method for the quantitative analysis of ceritinib in human plasma and its application to pharmacokinetic studies

Analytical and Bioanalytical Chemistry

Volumn , Issue , 2014, Pages 7389-7396

  Heudi, Olivier ^a   Vogel, Denise ^a   Lau, Yvonne Y ^a   Picard, Franck ^a   Kretz, Olivier ^a  

^a NOVARTIS PHARMA AG   (Switzerland)

Author keywords

Anaplastic lymphoma kinase; LC MS MS; Non small cell lungcancer; Pharmacokinetic; Validation

Indexed keywords

ACETONITRILE; DIGITAL STORAGE; DISEASES; DRUG PRODUCTS; ELECTROSPRAY IONIZATION; ENZYMES; FORMIC ACID; LIQUID CHROMATOGRAPHY; LIQUIDS; MASS SPECTROMETRY; ONCOLOGY; PHARMACOKINETICS; PLASMA (HUMAN); PLASMA STABILITY;

ANAPLASTIC LYMPHOMA KINASE; ELECTROSPRAY IONIZATION (ESI); LC-MS/MS; LIQUID CHROMATOGRAPHY TANDEM MASS SPECTROMETRY (LC MS/MS); LIQUID CHROMATOGRAPHY-TANDEM MASS SPECTROMETRY; LOW LIMIT OF QUANTIFICATIONS; NON SMALL CELL LUNG CANCER; VALIDATION;

EXTRACTION;

ANTINEOPLASTIC AGENT; CERITINIB; PYRIMIDINE DERIVATIVE; SULFONE;

BLOOD; HUMAN; LIQUID CHROMATOGRAPHY; LIQUID LIQUID EXTRACTION; METABOLISM; NEOPLASMS; PHASE 1 CLINICAL TRIAL (TOPIC); PROCEDURES; TANDEM MASS SPECTROMETRY; TISSUE DISTRIBUTION;

ANTINEOPLASTIC AGENTS; CHROMATOGRAPHY, LIQUID; CLINICAL TRIALS, PHASE I AS TOPIC; HUMANS; LIQUID-LIQUID EXTRACTION; NEOPLASMS; PYRIMIDINES; SULFONES; TANDEM MASS SPECTROMETRY; TISSUE DISTRIBUTION;

EID: 84937511710     PISSN: 16182642     EISSN: 16182650     Source Type: Journal    
DOI: 10.1007/s00216-014-8125-9     Document Type: Article

References (8)

1. Jemal A, Siegel R, Ward E, Hao Y, Xu J, Murray T, Thun MJ (2008) Cancer statistics, 2008. CA Cancer J Clin 58(2):71-96. doi:10.3322/ca.2007.0010
2. Koivunen JP, Mermel C, Zejnullahu K, Murphy C, Lifshits E, Holmes AJ, Choi HG, Kim J, Chiang D, Thomas R, Lee J, Richards WG, Sugarbaker DJ, Ducko C, Lindeman N, Marcoux JP, Engelman JA, Gray NS, Lee C, Meyerson M, Janne PA (2008) EML4-ALK fusion gene and efficacy of an ALK kinase inhibitor in lung cancer. Clin Cancer Res Off J Am Assoc Cancer Res 14(13):4275-4283. doi:10.1158/1078-0432.CCR-08-0168
3. Martelli MP, Sozzi G, Hernandez L, Pettirossi V, Navarro A, Conte D, Gasparini P, Perrone F, Modena P, Pastorino U, Carbone A, Fabbri A, Sidoni A, Nakamura S, Gambacorta M, Fernandez PL, Ramirez J, Chan JK, Grigioni WF, Campo E, Pileri SA, Falini B (2009) EML4-ALK rearrangement in non-small cell lung cancer and non-tumor lung tissues. Am J Pathol 174(2):661-670. doi:10.2353/ajpath.2009.080755
4. Shaw AT, Solomon B (2011) Targeting anaplastic lymphoma kinase in lung cancer. Clin Cancer Res Off J Am Assoc Cancer Res 17(8):2081-2086. doi:10.1158/1078-0432.CCR-10-1591
5. Marsilje TH, Pei W, Chen B, Lu W, Uno T, Jin Y, Jiang T, Kim S, Li N, Warmuth M, Sarkisova Y, Sun F, Steffy A, Pferdekamper AC, Li AG, Joseph SB, Kim Y, Liu B, Tuntland T, Cui X, Gray NS, Steensma R, Wan Y, Jiang J, Chopiuk G, Li J, Gordon WP, Richmond W, Johnson K, Chang J, Groessl T, He YQ, Phimister A, Aycinena A, Lee CC, Bursulaya B, Karanewsky DS, Seidel HM, Harris JL, Michellys PY (2013) Synthesis, structure-activity relationships, and in vivo efficacy of the novel potent and selective anaplastic lymphoma kinase (ALK) inhibitor 5-chloro-N2-(2-isopropoxy-5-methyl-4-(piperidin-4-yl)phenyl)-N4-(2-(isopropylsulf onyl)phenyl)pyrimidine-2,4-diamine (LDK378) currently in phase 1 and phase 2 clinical trials. J Med Chem 56(14):5675-5690. doi:10.1021/jm400402q
6. Shaw AT, Kim DW, Mehra R, Tan DS, Felip E, Chow LQ, Camidge DR, Vansteenkiste J, Sharma S, De Pas T, Riely GJ, Solomon BJ, Wolf J, Thomas M, Schuler M, Liu G, Santoro A, Lau YY, Goldwasser M, Boral AL, Engelman JA (2014) Ceritinib in ALK-rearranged non-small-cell lung cancer. N Engl J Med 370(13):1189-1197. doi:10.1056/NEJMoa1311107
7. Guidance for Industry: Bioanalytical Method ValidationUS Department of Health and Human Services FaDA, Center for Drug Evaluation and Research, Rockville, MD (2001) Available from: http://www.fda.gov/CVM (2001)
8. European Medicines Agency (2012) Guideline on bioanalytical method validation